ANI Pharmaceuticals Quarterly Balance Sheet
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ANI Pharmaceuticals financial position
As of Jun 30, 2026, ANI Pharmaceuticals reported total assets of $1.49 billion, up 11.3% from a year earlier against total liabilities of $896.9 million. Shareholders' equity stood at $597.2 million, or 40.0% of assets. The company held $360.2 million in cash and equivalents against $301.5 million of debt, a net cash position of $58.7 million.
The current ratio (current assets divided by current liabilities) was 2.91, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.50.
Summary generated from market data by MetaCap's automated system. Methodology
ANI Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 360.21M | 311.18M | 285.58M | 262.61M | 217.83M | 149.80M | 144.89M | 144.98M | 240.11M | 228.60M | 221.12M | 193.08M |
| Receivables | 274.47M | 255.43M | 281.08M | 252.62M | 225.65M | 220.33M | 221.73M | 196.36M | 166.09M | 172.42M | 162.08M | 178.84M |
| Inventory | 143.15M | 143.47M | 143.07M | 146.47M | 138.31M | 137.41M | 136.78M | 148.04M | 125.45M | 113.84M | 111.20M | 106.59M |
| Total Current Assets | 825.43M | 747.08M | 753.12M | 698.40M | 602.63M | 536.29M | 528.46M | 521.30M | 555.46M | 540.56M | 519.82M | 497.22M |
| Property, Plant & Equipment | 73.22M | 67.11M | 62.48M | 63.56M | 59.25M | 58.18M | 56.86M | 56.70M | 51.64M | 48.53M | 44.59M | 44.19M |
| Goodwill | 62.48M | 62.48M | 62.48M | 62.48M | 60.53M | 60.66M | 59.99M | 60.43M | 28.22M | 28.22M | 28.22M | 28.22M |
| Intangible Assets | 449.86M | 467.16M | 479.53M | 499.82M | 520.32M | 538.50M | 541.83M | 569.83M | 183.08M | 196.04M | 209.01M | 219.83M |
| Total Assets | 1.49B | 1.42B | 1.44B | 1.41B | 1.34B | 1.29B | 1.28B | 1.29B | 920.75M | 914.52M | 904.42M | 889.91M |
| Accounts Payable | 73.83M | 69.69M | 62.58M | 69.80M | 54.57M | 53.06M | 45.66M | 60.89M | 48.68M | 49.43M | 36.68M | 34.08M |
| Short-Term Debt | 21.33M | 19.30M | 17.27M | 15.24M | 13.22M | 11.19M | 9.17M | 7.15M | 850.00K | 850.00K | 850.00K | 850.00K |
| Total Current Liabilities | 283.65M | 239.51M | 278.11M | 270.56M | 236.84M | 201.81M | 194.45M | 189.93M | 139.98M | 136.89M | 145.48M | 134.35M |
| Long-Term Debt | 280.15M | 286.00M | 291.84M | 297.68M | 301.48M | 305.29M | 309.11M | 312.92M | 284.39M | 284.61M | 284.82M | 285.03M |
| Total Liabilities | 896.90M | 859.67M | 899.65M | 902.34M | 881.39M | 848.96M | 855.94M | 856.58M | 440.14M | 437.71M | 446.82M | 435.20M |
| Shareholders' Equity | 597.21M | 562.30M | 540.72M | 505.82M | 436.76M | 418.62M | 403.68M | 405.95M | 455.76M | 451.96M | 432.75M | 429.86M |
| Retained Earnings | 31.10M | 6.39M | -23.10M | -50.59M | -76.86M | -85.00M | -100.28M | -89.60M | -65.03M | -62.33M | -80.13M | -80.88M |
| Total Debt | 301.48M | 305.29M | 309.11M | 312.92M | 314.70M | 316.49M | 318.28M | 320.07M | 285.24M | 285.46M | 285.67M | 285.88M |
| Net Cash (Debt) | 58.73M | 5.88M | -23.52M | -50.31M | -96.87M | -166.69M | -173.39M | -175.09M | -45.13M | -56.86M | -64.55M | -92.80M |
| Shares Outstanding | — | — | 22.49M | — | — | — | 21.11M | — | — | — | — | — |
This table shows 12 quarterly periods of ANI Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow ANIP's reporting calendar. What is a balance sheet?